MaxCyte,
Inc.
("MaxCyte" or the "Company")
Grant of Options and
Restricted Stock Units
ROCKVILLE, MD, June 14, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and
commercialization of next-generation cell therapeutics and to
support innovative, cell-based research, announces that on 11 June
2024, a total of 325,608 options ("Option Grants") in respect of
common stock in the Company ("Common Stock"), and 170,936
restricted stock units ("RSU"s) were granted to PDMRs who are
non-executive directors of the Company. These Options Grants and
RSUs were made pursuant to the Company's Equity Grant Policy for
non-executive directors.
Details of the Option Grants are given
below:
|
Option Grants to
PDMRs
|
|
|
Al-Wakeel,
Yasir
|
40,701
|
|
Brooke,
Will
|
40,701
|
|
Balthrop,
Patrick
|
40,701
|
|
Douglas,
Richard
|
40,701
|
|
Erck,
Stanley
|
40,701
|
|
Hemrajani,
Rekha
|
40,701
|
|
Johnston,
John
|
40,701
|
|
Mandell,
Art
|
40,701
|
|
Total
|
325,608
|
Option Grants for non-executive directors fully vest
at the end of twelve (12) months after date of grant. (1 year
cliff until fully vested).
The Options Grants have an exercise
period of 10 years from date of grant, at which time they will
expire, and have an exercise price equal to the closing price of
MaxCyte's stock on 11 June 2024, of $4.68 on the United States
Nasdaq Stock Exchange.
Details of the RSUs are given below:
|
Option Grants to
PDMRs
|
|
|
Al-Wakeel,
Yasir
|
21,367
|
|
Brooke,
Will
|
21,367
|
|
Balthrop,
Patrick
|
21,367
|
|
Douglas,
Richard
|
21,367
|
|
Erck,
Stanley
|
21,367
|
|
Hemrajani,
Rekha
|
21,367
|
|
Johnston,
John
|
21,367
|
|
Mandell,
Art
|
21,367
|
|
Total
|
170,936
|
About MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our
ExPERT™ platform, which is based on our Flow
Electroporation®
technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™,
GTx™ and VLx ™; a portfolio of proprietary related
processing assemblies or disposables; and software protocols, all
supported by a robust worldwide intellectual property portfolio.
By providing our partners with the right technology, as well
as technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more
at maxcyte.com and
follow us on Twitter and LinkedIn.
MaxCyte Contacts:
|
US IR
Adviser
Gilmartin
Group
David
Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
|
Nominated Adviser and Joint
Corporate Broker
Panmure
Gordon
Emma Earl /
Freddy Crossley
Corporate
Broking
Rupert
Dearden
|
+44 (0)20 7886 2500
|
|
UK IR
Adviser
Consilium Strategic
Communications
Mary-Jane
Elliott
Chris
Welsh
|
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
a) Yasir
Al-Wakeel
b) Will
Brooke
c) Patrick
Balthrop
d) Richard
Douglas
e) Stanley
Erck
f) Rekha
Hemrajani
g) John
Johnston
h) Art
Mandell
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
a) Non-Executive
Director
b) Non-Executive
Director
c) Non-Executive
Director
d) Non-Executive
Chairman
e) Non-Executive
Director
f)
Non-Executive Director
g) Non-Executive
Director
h) Non-Executive
Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MaxCyte Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Common Stock of $0.01 each
|
|
|
|
|
Identification code
|
US57777K1060
|
|
|
|
|
b)
|
Nature of the transaction
|
Grant of options of common stock
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Exercise Price(s)
|
Volume(s)
|
|
|
|
|
a)
$4.68
|
40,701
|
|
|
|
|
b)
$4.68
|
40,701
|
|
|
|
|
c)
$4.68
|
40,701
|
|
|
|
|
d)
$4.68
|
40,701
|
|
|
|
|
e)
$4.68
|
40,701
|
|
|
|
|
f)
$4.68
|
40,701
|
|
|
|
|
g)
$4.68
|
40,701
|
|
|
|
|
h)
$4.68
|
40,701
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
325,608
|
|
|
|
|
- Price
|
$4.68
|
|
|
|
|
e)
|
Date of the transaction
|
11 June 2024
|
|
f)
|
Place of the transaction
|
US Stock Exchange, Nasdaq
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
a) Yasir
Al-Wakeel
b) Will
Brooke
c) Patrick
Balthrop
d) Richard
Douglas
e) Stanley
Erck
f) Rekha
Hemrajani
g) John
Johnston
h) Art
Mandell
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
a) Non-Executive
Director
b) Non-Executive
Director
c) Non-Executive
Director
d) Non-Executive
Chairman
e) Non-Executive
Director
f)
Non-Executive Director
g) Non-Executive
Director
h) Non-Executive
Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MaxCyte Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Common Stock of $0.01 each
|
|
|
|
|
Identification code
|
US57777K1060
|
|
|
|
|
b)
|
Nature of the transaction
|
Grant of restricted stock units
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Exercise Price(s)
|
Volume(s)
|
|
|
|
|
i)
N/A
|
40,701
|
|
|
|
|
j)
N/A
|
40,701
|
|
|
|
|
k) N/A
|
40,701
|
|
|
|
|
l)
N/A
|
40,701
|
|
|
|
|
m) N/A
|
40,701
|
|
|
|
|
n) N/A
|
40,701
|
|
|
|
|
o) N/A
|
40,701
|
|
|
|
|
p) N/A
|
40,701
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
170,936
|
|
|
|
|
- Price
|
No exercise price for the
RSUs
|
|
|
|
|
e)
|
Date of the transaction
|
11 June 2024
|
|
f)
|
Place of the transaction
|
US Stock Exchange, Nasdaq
|